ClinicalTrials.gg
CompletedNCT00296400PLANET IIUpdated Jun 16, 2011Results posted

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

A Phase 2 interventional study of Rosuvastatin and Atorvastatin in Hyperlipidemia, sponsored by AstraZeneca. Completed at 107 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-16.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies testing rosuvastatin in Hyperlipidemias — 1 open to participants now, 1 under way, none of them phase 3. rosuvastatin · Hyperlipidemias.

Enrollment
10th of 30
237 · median 114
Started
2006
with 1 other
Phase 2
4 of 30
none open now
Registered
3rd of 30
by date
Lead sponsor
5 of 30
AstraZeneca

Among the 30 studies testing rosuvastatin in Hyperlipidemias, this one is the 10th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 2, and was the 3rd registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

1 of the 30 studies testing rosuvastatin in Hyperlipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing rosuvastatin in Hyperlipidemias, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.

03

Conditions studied

  • Hyperlipidemia

Keywords

  • Hyperlipidemia
  • Proteinuria
  • Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • greater than or equal to 18 years of age
  • Hyperlipidemia
  • Urinary protein

Exclusion criteria

Exclusion Criteria:

  • Previous rosuvastatin treatment \< 6 months prior to Visit 1
  • Statin intolerance
  • Severe hypertension
  • Diabetes
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
237 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Urinary Protein/Creatinine Ratio at Week 52 [LOCF]

    Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

    Time frame: Assessed at baseline and Week 52 (LOCF)

Secondary outcomes

  1. Urinary Protein/Creatinine Ratio at Week 26.

    Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

    Time frame: Assessed at baseline and Week 26

  2. Urinary Albumin/Creatinine Ratio at Week 26

    Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

    Time frame: Assessed at baseline and Week 26

  3. Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]

    Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

    Time frame: Assessed at baseline and Week 52 [LOCF]

  4. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26

    The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value.

    Time frame: Assessed at baseline and Week 26

  5. Change From Baseline in eGFR at Week 52 [LOCF]

    The change from baseline in eGFR at Week 52 \[LOCF\] is the Week 52 value or last observation carried forward minus baseline value.

    Time frame: Assessed at baseline and Week 52 [LOCF]

  6. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: baseline and 26 weeks

  7. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: 52 weeks

  8. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  9. Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: 52 weeks

  10. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: 26 weeks

  11. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  12. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship. )

    Time frame: Baseline and 26 weeks

  13. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  14. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  15. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  16. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  17. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  18. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  19. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  20. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  21. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  22. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  23. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  24. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  25. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  26. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  27. Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  28. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  29. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  30. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  31. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  32. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  33. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  34. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  35. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  36. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  37. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  38. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  39. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  40. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  41. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  42. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  43. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  44. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  45. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  46. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  47. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: 52 weeks

  48. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  49. Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  50. Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  51. Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  52. Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  53. Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  54. Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  55. Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  56. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  57. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  58. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  59. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  60. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  61. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  62. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  63. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  64. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  65. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  66. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  67. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  68. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  69. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

  70. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 26 weeks

  71. Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

    Time frame: Baseline and 52 weeks

07

Results

Posted Dec 30, 2010

Participant flow

797 patients entered the study with moderate proteinuria and hypercholesterolemia and were receiving stable treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) for 3 or more months prior to Visit 1. The study was conducted at 114 participating centers in 11 countries.

Participant flow — Overall Study
MilestoneRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
Started708780
Completed536967
Not completed171813
Withdrew: Adverse event777
Withdrew: Withdrawal by subject562
Withdrew: Incorrect enrollment200
Withdrew: Protocol violation111
Withdrew: Lost to follow-up112
Withdrew: Study specific discontinuation criteria001
Withdrew: Visit 10 was performed earlier010
Withdrew: Pregnancy120

Outcome measures

PrimaryUrinary Protein/Creatinine Ratio at Week 52 [LOCF]

Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

Time frame:
Assessed at baseline and Week 52 (LOCF)
Reported as:
Geometric mean · ratio
Urinary Protein/Creatinine Ratio at Week 52 [LOCF]
ratioRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
Urinary Protein/Creatinine Ratio at Week 52 [LOCF]0.938 (0.725 to 1.212)1.082 (0.927 to 1.262)0.759 (0.636 to 0.905)
SecondaryUrinary Protein/Creatinine Ratio at Week 26.

Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

Time frame:
Assessed at baseline and Week 26
Reported as:
Geometric mean · ratio
Urinary Protein/Creatinine Ratio at Week 26.
ratioRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
Urinary Protein/Creatinine Ratio at Week 26.0.932 (0.721 to 1.203)1.057 (0.898 to 1.244)0.762 (0.631 to 0.921)
SecondaryUrinary Albumin/Creatinine Ratio at Week 26

Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

Time frame:
Assessed at baseline and Week 26
Reported as:
Geometric mean · ratio
Urinary Albumin/Creatinine Ratio at Week 26
ratioRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
Urinary Albumin/Creatinine Ratio at Week 260.850 (0.631 to 1.143)0.946 (0.789 to 1.135)0.731 (0.601 to 0.889)
SecondaryUrinary Albumin/Creatinine Ratio at Week 52 [LOCF]

Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

Time frame:
Assessed at baseline and Week 52 [LOCF]
Reported as:
Geometric mean · ratio
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
ratioRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]0.879 (0.652 to 1.185)0.967 (0.814 to 1.148)0.719 (0.587 to 0.882)
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26

The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value.

Time frame:
Assessed at baseline and Week 26
Reported as:
Mean · mL/min
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
mL/minRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 261.39 ± 15.431-3.41 ± 13.228-1.61 ± 9.494
SecondaryChange From Baseline in eGFR at Week 52 [LOCF]

The change from baseline in eGFR at Week 52 \[LOCF\] is the Week 52 value or last observation carried forward minus baseline value.

Time frame:
Assessed at baseline and Week 52 [LOCF]
Reported as:
Mean · mL/min
Change From Baseline in eGFR at Week 52 [LOCF]
mL/minRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
Change From Baseline in eGFR at Week 52 [LOCF]-2.71 ± 13.083-3.30 ± 12.325-1.74 ± 13.964
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.0.176010.217010.19643
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.0.204620.034800.16077
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 260.143020.243930.17632
SecondaryCorrelation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C0.16868-0.094280.10679
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 260.180550.249870.22094
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 520.203460.180410.20818
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship. )

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 260.162060.200320.17628
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 520.20386-0.046980.14495
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 260.15348-0.060490.10089
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 520.206590.239890.21728
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 260.046520.063440.04149
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 520.03957-0.17644-0.01549
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 260.063830.126870.07462
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 520.05881-0.20262-0.01340
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 260.067940.054100.05465
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 520.07188-0.166690.00955
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 260.125950.056280.13754
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 520.196260.098350.18349
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 260.185040.172590.19146
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 520.18473-0.026900.12496
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 260.106980.138140.11414
SecondaryCorrelation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 520.05859-0.12938-0.00540
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 260.181880.175030.18566
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 520.237340.013110.17958
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 260.147830.215610.16899
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 520.20285-0.135650.12568
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 260.235470.250430.25208
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 520.174790.186770.18203
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 260.160800.171500.16578
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 520.24107-0.086400.16525
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 260.11526-0.068900.07248
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 520.217300.211510.21477
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 260.025060.022010.01860
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 520.08954-0.208700.01926
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 260.050370.097790.05936
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 520.10365-0.247170.01386
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 260.049550.027400.03798
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 520.11997-0.210730.03955
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 260.164990.026090.15049
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 520.200210.129530.18870
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 260.187200.161670.18717
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 520.21082-0.043790.14085
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 260.102580.135050.11103
SecondaryCorrelation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 520.08108-0.167530.00479
SecondaryCorrelation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 260.06641-0.079640.02900
SecondaryCorrelation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52-0.157210.16110-0.05794
SecondaryCorrelation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 260.02679-0.07603-0.00171
SecondaryCorrelation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52-0.157310.15368-0.06310
SecondaryCorrelation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 260.016840.017550.01758
SecondaryCorrelation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 520.140800.027500.09472
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 260.06029-0.081510.02283
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52-0.195320.14967-0.09001
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 260.041600.005310.03430
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in TG

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG-0.126430.00486-0.08301
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 260.08194-0.065760.04477
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52-0.235970.19933-0.10205
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 260.04858-0.055350.02023
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52-0.208050.18299-0.07681
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 260.08263-0.068600.04337
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52-0.238870.17170-0.10817
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 260.130290.175540.14191
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 520.110470.077510.08580
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 260.06098-0.031810.03861
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52-0.112170.11006-0.03932
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 26 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 260.02907-0.09476-0.00160
SecondaryCorrelation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

Time frame:
Baseline and 52 weeks
Reported as:
Number · Correlation coefficient
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Correlation coefficientRosuvastatinAtorvastatinAll Treatments
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52-0.154150.10486-0.06121

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 10 mg—10/69 (14.5%)15/69 (21.7%)
Rosuvastatin 40 mg—6/87 (6.9%)16/87 (18.4%)
Atorvastatin 80 mg—5/80 (6.3%)17/80 (21.3%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
BronchitisInfections and infestations2/690/871/80
Cardiac FailureCardiac disorders1/690/870/80
Cardiac Failure CongestiveCardiac disorders1/690/870/80
EnterocolitisGastrointestinal disorders1/690/870/80
Lumbar Vertebral FractureInjury, poisoning and procedural complications1/690/870/80
Fluid RetentionMetabolism and nutrition disorders1/690/870/80
Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders1/690/870/80
Transitional Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/690/870/80
Hypertensive EncephalopathyNervous system disorders1/690/870/80
Renal ColicRenal and urinary disorders1/690/870/80
Most frequent other events
Most frequent other events
EventRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
NasopharyngitisInfections and infestations3/696/877/80
NauseaGastrointestinal disorders2/696/870/80
MyalgiaMusculoskeletal and connective tissue disorders4/693/875/80
BronchitisInfections and infestations4/690/870/80
Blood Creatine Phosphokinase IncreasedInfections and infestations3/693/874/80
DizzinessNervous system disorders0/691/874/80

Baseline characteristics

Age, Customized
Age, Customized(Participants)Rosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mgTotal
18 to 49 years344442120
50 to 64 years31313092
>=65 years512825
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mgTotal
Female28 (28 to —)35 (35 to —)31 (31 to —)94 (0 to 0)
Male42 (42 to —)52 (52 to —)49 (49 to —)143 (0 to 0)
Estimated glomerular filtration rate [eGFR]
Estimated glomerular filtration rate [eGFR](mL/min)Rosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mgTotal
Mean78.315 ± 28.065376.774 ± 30.387871.464 ± 30.015675.419 ± 29.6012
Urine albumin/creatinine ratio
Urine albumin/creatinine ratio(mg/g)Rosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mgTotal
Mean1023.165 ± 720.02511167.368 ± 865.45841069.103 ± 720.80111091.263 ± 775.1889
Urine protein/creatinine ratio
Urine protein/creatinine ratio(mg/g)Rosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mgTotal
Mean1301.163 ± 832.73981487.131 ± 1068.06421439.720 ± 991.22951416.023 ± 975.7636
08

Study locations

107 sites
  • Research Site
    Avondale, Arizona, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Pasadena, California, United States
  • Research Site
    Riverside, California, United States
  • Research Site
    Clearwater, Florida, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Augusta, Georgia, United States
  • Research Site
    Topeka, Kansas, United States
  • Research Site
    Columbia, Maryland, United States
  • Research Site
    Springfield, Massachusetts, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Columbia, Missouri, United States
  • Research Site
    Orchard Park, New York, United States
  • Research Site
    Winston Salem, North Carolina, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Columbia, South Carolina, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Richmond, Virginia, United States
  • Research Site
    Gig Harbor, Washington, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Curitiba, PR, Brazil
  • Research Site
    Sao Paulo, SP, Brazil
  • Research Site
    Blagoevgrad, Bulgaria
  • Research Site
    Burgas, Bulgaria
  • Research Site
    Gabrovo, Bulgaria
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Plovdiv, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Veliko Turnovo, Bulgaria
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    St John's, Newfoundland and Labrador, Canada
  • Research Site
    Courtice, Ontario, Canada
  • Research Site
    East York, Ontario, Canada
  • Research Site
    Oakville, Ontario, Canada
  • Research Site
    Oshawa, Ontario, Canada
  • Research Site
    Richmond Hill, Ontario, Canada
  • Research Site
    Scarborough, Ontario, Canada
  • Research Site
    Thunder Bay, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Greenfield Park, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Fredericia, Denmark
  • Research Site
    Herlev, Denmark
  • Research Site
    Holbaek, Denmark
  • Research Site
    Kobenhavn, Denmark
  • Research Site
    Roskilde, Denmark
  • Research Site
    Viborg, Denmark
  • Research Site
    Berlin, Germany
  • Research Site
    Cloppenburg, Germany
  • Research Site
    Demmin, Germany
  • Research Site
    Dusseldorf, Germany
  • Research Site
    Elsenfeld, Germany
  • Research Site
    Gottingen, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Wurzburg, Germany
  • Research Site
    Ajka, Hungary
  • Research Site
    Baja, Hungary
  • Research Site
    Balatonfured, Hungary
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Eger, Hungary
  • Research Site
    Gyula, Hungary
  • Research Site
    Gy�r, Hungary
  • Research Site
    Keszthely, Hungary
  • Research Site
    Miskolc, Hungary
  • Research Site
    Nyiregyhaza, Hungary
  • Research Site
    Szolnok, Hungary
  • Research Site
    Szombathely, Hungary
  • Research Site
    Zalaegerszeg, Hungary
  • Research Site
    Bergamo, BG, Italy
  • Research Site
    Bologna, BO, Italy
  • Research Site
    Brescia, BS, Italy
  • Research Site
    Acireale, CT, Italy
  • Research Site
    Foggia, FG, Italy
  • Research Site
    Firenze, FI, Italy
  • Research Site
    Parma, PR, Italy
  • Research Site
    Reggio Calabria, RC, Italy
  • Research Site
    Sassari, SS, Italy
  • Research Site
    Teramo, TE, Italy
  • Research Site
    Torino, TO, Italy
  • Research Site
    Castelfranco Veneto, TV, Italy
  • Research Site
    Treviso, TV, Italy
  • Research Site
    Mestre, VE, Italy
  • Research Site
    Mexico, DF, Mexico
  • Research Site
    Zapopan, Jalisco, Mexico
  • Research Site
    Cuernavaca, Morelos, Mexico
  • Research Site
    Aguascalientes, Mexico
  • Research Site
    D.F, Mexico
  • Research Site
    Durango, Mexico
  • Research Site
    San Luis Potos�, Mexico
  • Research Site
    Cluj Napoca, Cluj, Romania
  • Research Site
    Timisoara, Timis, Romania
  • Research Site
    Brasov, Romania
  • Research Site
    Bucuresti, Romania
  • Research Site
    Constanta, Romania
  • Research Site
    Craiova, Romania

Showing the first 100 of 107 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90. doi: 10.1016/S2213-8587(14)70246-3. Epub 2015 Feb 4. PubMed 25660356 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2006
First posted
Feb 27, 2006
Start
Feb 2006
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Dec 30, 2010
Last update
Jun 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00296400
Lead sponsor
AstraZeneca
First posted
Feb 27, 2006
Start date
Feb 2006
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Dec 30, 2010
Last update
Jun 16, 2011

Study contacts

AstraZeneca Crestor Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Atorvastatin

Start the discussion